Gonorrhoea: One of the most common sexually transmitted diseases (STDs), is witnessing a global surge, with the World Health Organization (WHO) estimating over 82 million infections annually. The African region has been particularly affected, grappling with high infection rates.
The situation has worsened with the rise of drug-resistant strains, which WHO has classified as a “priority pathogen.” Alarmingly, gonorrhoea occurrence rates were three times higher in 2023 than previous years.
In a major breakthrough, the approval of new antibiotics has been hailed as a turning point in the fight against drug-resistant gonorrhoea.
Zoliflodacin, one of the newly approved treatments, received US FDA approval on December 12. Clinical trials published in The Lancet showed that zoliflodacin was effective against 90 percent of genital gonorrhoea infections. While targeted use of the drug may carry some risks, researchers say it will help slow the spread of resistant pathogens.
Another antibiotic, Gepotidacin, developed by pharmaceutical company GSK, was also approved recently as an effective treatment for drug-resistant gonorrhoea.
Dr Manica Balasegaram, Executive Director of GARDP, described the approvals as a “huge turning point in the treatment of multidrug-resistant gonorrhoea, which until now had been outpacing antibiotic development.”
Dr Rossaphorn Kittiyaowamarn, principal investigator of the Thai clinical trial, emphasized the significance: “As clinicians, we see the devastating impact drug-resistant gonorrhoea has on people’s lives. Having a single-dose oral treatment will be a game-changer, reducing the burden of disease and preventing the global spread of highly drug-resistant gonorrhoea.”
These developments offer a critical new weapon in the ongoing battle against a growing public health threat.
